Improved
6121 HealthChanged
3792 LivesSaved
3577 Lives0 lives impacted in the last 24 hrs Learn More
The US Food & Drug Administration (FDA) Advisory Committee just voted 9-2, with 1 abstaining, to recommend that the FDA approve rivaroxaban (Xarelto) for prevention of atrial fibrillation strokes. See our full story, now up at:
FDA Panel Votes for Rivaroxaban: Atrial Fibrillation Patients May Soon Have Two Alternatives to Warfarin for Stroke Prevention
http://bit.ly/r8bbWI
All user-generated information on this site is the opinion of its author only and is not a substitute for medical advice or treatment for any medical conditions. Members and guests are responsible for their own posts and the potential consequences of those posts detailed in our Terms of Service.
Add a Comment1 Comments
Thank you for sharing this recent development in drug therapy for the prevention of atrial fibrillation strokes.
September 12, 2011 - 4:09pmMaryann
This Comment